Clearside Biomedical, Inc.

CLSDQ

Clearside Biomedical, Inc.

CLSDQ

Insider Sentiment (TTM):

Last Purchase:2025-02-24Last Sale:2024-01-19Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:2025-12-31Institutional Shares Owned:27,136Shares Outstanding:5,233,981Institutional Ownership Pct.:0.52%

Earnings Market Reaction:

Filing Date:2025-11-14Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Assets
Cash And Cash Equivalents At Carrying Value	7	9	14	20	14	18	35	29	29	35	41	48
Assets Current
Assets Current	8	12	16	21	25	30	36	30	31	36	43	49
Short Term Investments	-	-	-	-	10	11	-	-	-	-	-	-
Accounts Receivable Net Current	0	1	2	1	1	0	0	0	1	0	-	0
Prepaid Expense Current	1	2	1	1	1	0	1	1	1	1	1	1
Other Assets Current	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	3	3	3	3	3	3	3	3	3	2	1	1
Operating Lease Right Of Use Asset	0	0	1	1	1	1	1	1	1	1	1	1
Other Assets Noncurrent	0	0	0	0	0	0	0	0	0	0	0	0
Restricted Cash And Cash Equivalents Noncurrent	-	-	-	-	-	-	-	-	-	-	-	0
Assets	12	15	20	25	29	34	40	34	34	39	45	51
Liabilities And Stockhold…
Accounts Payable Current	1	1	2	1	2	2	1	2	2	2	2	1
Accrued Liabilities Current	2	2	3	3	3	4	4	4	4	3	3	4
Liabilities Current
Liabilities Current	3	3	5	5	6	6	6	7	6	5	5	6
Operating Lease Liability Current	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Revenue Current	-	-	-	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	0	0	0	0	0	0	1	1	1	1	1	1
Other Liabilities Noncurrent	-	-	-	0	-	-	-	0	-	-	-	0
Liabilities	66	64	66	64	64	62	62	50	47	44	42	41
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity
Additional Paid In Capital	320	319	318	316	313	312	311	305	303	302	300	299
Stockholders Equity	-54	-49	-46	-39	-35	-28	-22	-16	-13	-5	3	11
Retained Earnings Accumulated Deficit	-374	-368	-363	-355	-348	-340	-333	-321	-316	-307	-298	-288
Accumulated Other Comprehensive Income Loss Net Of…	-	-	-	-	0	-0	-	-	-	-	-	-
Liabilities And Stockholders Equity	12	15	20	25	29	34	40	34	34	39	45	51
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	27	400	200	200	200	200	200	200	200	200	200	200
Common Stock Shares Issued	5	5	5	5	5	5	5	4	4	4	4	4
Shares Outstanding	5	5	5	5	5	5	5	4	4	4	4	4

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2025	-9.02%	-6.13%	-55.61%	-9.80%	-33.99%	-36.27%	-79.32%	-80.37%	-80.37%	-	-	-
2024	12.00%	4.00%	-6.40%	-9.35%	35.51%	-5.61%	-7.21%	-12.61%	-16.22%	-16.50%	-14.66%	-22.33%
2023	9.52%	6.67%	16.19%	-18.87%	-16.89%	-9.91%	12.37%	38.14%	41.24%	-20.73%	-20.12%	-14.63%
2022	-	-	-	-	-	-	-	-	-	20.39%	-1.94%	11.65%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31
Liquidity Ratios
Current Ratio	2.98	3.87	3.19	4.44	4.49	5.07	6.07	4.42	5.28	6.85	8.54	8.54
Quick Ratio	2.55	3.35	3.04	4.28	4.36	5.01	5.97	4.32	5.09	6.74	8.39	8.42
Working Capital	5.48M	8.74M	10.95M	16.48M	19.52M	23.89M	30.17M	23.31M	24.98M	30.83M	37.58M	43.62M
Leverage & Debt
Debt to Equity	-1.22	-1.31	-1.43	-1.65	-1.84	-2.20	-2.84	-3.14	-3.68	-8.88	15.55	3.84
Debt Ratio	5.63	4.18	3.33	2.55	2.19	1.83	1.54	1.47	1.37	1.13	0.94	0.79
Efficiency & Turnover
Asset Turnover TTM	0.16	0.17	0.13	0.06	0.24	0.21	0.20	0.19	0.05	0.05	0.02	0.03
Days Sales Outstanding TTM	57.78	71.49	149.14	106.82	39.57	-	-	20.72	145.60	57.52	-	-
Receivables Turnover TTM	6.32	5.11	2.45	3.42	9.23	-	-	17.61	2.51	6.35	-	-
Per Share Metrics
Diluted EPS TTM	-4.97	-5.34	-6.01	-6.98	-6.40	-6.71	-7.51	-7.88	-9.03	-8.72	-8.48	-8.20
Free Cash Flow Per Share TTM	-4.15	-4.28	-4.60	-5.22	-3.93	-4.04	-4.40	-4.83	-6.29	-6.28	-6.08	-3.39
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-689.76%	-524.63%	-687.51%	-1,735.70%	-319.98%	-342.48%	-301.09%	-302.02%	-1,356.81%	-1,833.68%	-3,072.76%	-2,281.61%
Net Profit Margin TTM	-780.93%	-665.22%	-818.60%	-2,064.42%	-413.83%	-444.66%	-413.72%	-394.91%	-1,687.74%	-2,217.31%	-3,514.53%	-2,482.82%
Growth Metrics
Net Revenue Growth (1Y)	-56.78%	-44.63%	-55.47%	-79.77%	248.39%	365.02%	758.94%	519.89%	-91.71%	-94.51%	-96.71%	-95.51%
Net Income Growth (1Y)	-18.45%	-17.17%	-11.89%	5.75%	-14.58%	-6.75%	1.11%	-1.40%	715.65%	2,094.25%	-41,766.27%	-8,862.50%
EPS Growth (1Y)	-22.36%	-20.48%	-19.98%	-11.44%	-29.12%	-23.06%	-11.46%	-3.96%	692.02%	2,040.72%	-41,013.39%	-8,613.20%
Calculated Values
Free Cash Flow TTM	-21.75M	-22.23M	-23.61M	-25.68M	-19.60M	-20.16M	-20.49M	-19.91M	-25.99M	-25.81M	-24.81M	-13.61M
Net Debt	-6.80M	-9.38M	-13.63M	-20.02M	-13.89M	-18.24M	-35.36M	-28.92M	-28.80M	-35.01M	-41.42M	-48.26M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2025-02-24Purchase

Owner: Thorp, Clay

Title: -

Shares: 15,000

Price/Share: $0.92

Value: $13,800.00

Shares Owned: 176,141

Relationship: Director

Ownership: Direct

2024-11-01Purchase

Owner: Chong, Ngai Hang Victor

Title: Chief Medical Officer

Shares: 36,500

Price/Share: $1.00

Value: $36,500.00

Shares Owned: 100,000

Relationship: Officer

Ownership: Direct

2024-06-24Purchase

Owner: Chong, Ngai Hang Victor

Title: Chief Medical Officer

Shares: 23,500

Price/Share: $1.06

Value: $24,910.00

Shares Owned: 63,500

Relationship: Officer

Ownership: Direct

2024-05-15Purchase

Owner: Yerxa, Benjamin R

Title: -

Shares: 7,813

Price/Share: $1.31

Value: $10,235.03

Shares Owned: 17,957

Relationship: Director

Ownership: Direct

2024-04-18Purchase

Owner: Gibney, Anthony S

Title: -

Shares: 93,290

Price/Share: $1.30

Value: $121,277.00

Shares Owned: 100,000

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2025-02-24	Thorp, Clay	Director	-	Direct	Purchase	15,000	0.92	$13,800.00	176,141	4
2024-11-01	Chong, Ngai Hang Victor	Officer	Chief Medical Officer	Direct	Purchase	36,500	1.00	$36,500.00	100,000	4
2024-06-24	Chong, Ngai Hang Victor	Officer	Chief Medical Officer	Direct	Purchase	23,500	1.06	$24,910.00	63,500	4
2024-05-15	Yerxa, Benjamin R	Director	-	Direct	Purchase	7,813	1.31	$10,235.03	17,957	4
2024-04-18	Gibney, Anthony S	Director	-	Direct	Purchase	93,290	1.30	$121,277.00	100,000	4
2024-03-20	Chong, Ngai Hang Victor	Officer	CHIEF MEDICAL OFFICER	Direct	Purchase	30,000	1.60	$48,000.00	30,000	4
2024-02-07	Whitmore, Bradford T	TenPercentOwner	-	Direct	Purchase	444,444	1.35	$599,999.40	4,495,034	4
2024-01-19	Lasezkay, George M	Director,Officer	CEO	Direct	Sale	18,000	1.27	$22,860.00	466,577	4
2024-01-19	Deignan, Charles A.	Officer	Chief Financial Officer	Direct	Sale	12,900	1.28	$16,512.00	384,662	4
2023-11-01	Whitmore, Bradford T	TenPercentOwner	-	Direct	Purchase	64,366	0.74	$47,630.84	4,050,590	4
2023-10-03	Hutson, Nancy J	Director	-	Direct	Purchase	10,000	0.86	$8,600.00	93,000	4
2023-09-25	Thorp, Clay	Director	-	Direct	Purchase	10,000	0.86	$8,600.00	40,522	4
2023-01-20	Ciulla, Thomas	Officer	Chief Medical Officer	Direct	Sale	13,700	1.47	$20,139.00	291,890	4
2023-01-19	Lasezkay, George M	Director,Officer	CEO	Direct	Sale	20,030	1.46	$29,243.80	484,577	4
2023-01-19	Deignan, Charles A.	Officer	Chief Financial Officer	Direct	Sale	14,030	1.50	$21,045.00	363,472	4
2023-01-10	Ciulla, Thomas	Officer	Chief Medical Officer	Direct	Sale	2,170	1.62	$3,515.40	305,590	4
2022-12-21	Thorp, Clay	Director	-	Direct	Purchase	14,000	1.02	$14,280.00	30,522	4
2022-11-17	Hutson, Nancy J	Director	-	Direct	Purchase	30,000	1.33	$39,900.00	83,000	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2025-12-31

0.52%

Inst. Shares: 27,136

Shares Outstanding: 5,233,981

2025-09-30

10.27%

Inst. Shares: 537,337

Shares Outstanding: 5,233,981

2025-06-30

11.28%

Inst. Shares: 585,919

Shares Outstanding: 5,192,198

2025-03-31

11.11%

Inst. Shares: 569,898

Shares Outstanding: 5,130,687

2024-12-31

12.70%

Inst. Shares: 625,080

Shares Outstanding: 4,922,683

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2025-12-31	27,136	5,233,981	0.52%
2025-09-30	537,337	5,233,981	10.27%
2025-06-30	585,919	5,192,198	11.28%
2025-03-31	569,898	5,130,687	11.11%
2024-12-31	625,080	4,922,683	12.70%
2024-09-30	668,530	4,983,032	13.42%
2024-06-30	913,861	4,984,567	18.33%
2024-03-31	993,202	4,659,210	21.32%
2023-12-31	485,570	4,122,524	11.78%
2023-09-30	493,721	4,134,332	11.94%
2023-06-30	529,917	4,112,356	12.89%
2023-03-31	528,634	4,080,005	12.96%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Clearside Biomedical, Inc. (CLSDQ) — SEC Financial Statements & Analysis

Clearside Biomedical, Inc. (CLSDQ) is a pharmaceutical preparations company, incorporated in DE. Clearside Biomedical, Inc. trades on OTC as: CLSDQ. Based on its latest SEC filing (Form 10-Q, period ending 2025-09-30), Clearside Biomedical, Inc. reported a -56.78% year-over-year revenue growth, a Debt-to-Equity ratio of -1.22x. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -56.78%
Debt To Equity: -1.22x

Data as of 2025-09-30 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Clearside Biomedical, Inc. in?

Clearside Biomedical, Inc. (CLSDQ) operates in the Pharmaceutical Preparations industry.

What exchange does CLSDQ trade on?

Clearside Biomedical, Inc. (CLSDQ) trades on the OTC.

Where is Clearside Biomedical, Inc. incorporated?

Clearside Biomedical, Inc. is incorporated in DE.